Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Humacyte Inc (HUMA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/24/2025: HUMA (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -51.51% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 301.19M USD | Price to earnings Ratio - | 1Y Target Price 12.14 |
Price to earnings Ratio - | 1Y Target Price 12.14 | ||
Volume (30-day avg) 2127440 | Beta 1.36 | 52 Weeks Range 1.76 - 9.97 | Updated Date 03/30/2025 |
52 Weeks Range 1.76 - 9.97 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.34 |
Earnings Date
Report Date 2025-03-20 | When Before Market | Estimate -0.255 | Actual -0.2091 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -53.74% | Return on Equity (TTM) -850.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 297886228 | Price to Sales(TTM) 153.91 |
Enterprise Value 297886228 | Price to Sales(TTM) 153.91 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 4.34 | Shares Outstanding 153668000 | Shares Floating 94356333 |
Shares Outstanding 153668000 | Shares Floating 94356333 | ||
Percent Insiders 22.76 | Percent Institutions 29.65 |
Analyst Ratings
Rating 4.57 | Target Price 13.71 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Humacyte Inc
Company Overview
History and Background
Humacyte Inc. is a biotechnology company focused on developing and manufacturing human acellular vessels (HAVs) for various vascular repair, reconstruction, and replacement applications. Founded in 2004, it has focused on engineering readily available, off-the-shelf HAVs to overcome limitations of existing therapies.
Core Business Areas
- Human Acellular Vessels (HAVs): The primary business area focuses on the development, manufacturing, and commercialization of HAVs. These are bioengineered blood vessels intended for various applications, including dialysis access, peripheral arterial disease (PAD), and vascular trauma repair.
- Research and Development: Extensive R&D efforts are directed towards expanding the applications of HAV technology, improving manufacturing processes, and exploring new therapeutic areas.
Leadership and Structure
The company is led by Laura Niklason, M.D., Ph.D., the founder and CEO. The leadership team comprises individuals with expertise in biotechnology, manufacturing, clinical development, and commercialization. The organizational structure is typical of a biotechnology company, with functional departments such as R&D, manufacturing, clinical affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- HUMACYLu00ae (HAV for AV access): HUMACYL is Humacyte's lead product candidate, designed for arteriovenous (AV) access in hemodialysis patients. It addresses the need for a readily available, infection-resistant alternative to synthetic grafts and autologous fistulas. As of now, HUMACYLu00ae is not approved in US. The product is still in trial phase. Competitors include W. L. Gore & Associates (Gore-Tex Vascular Grafts) and Getinge (ePTFE grafts) in vascular grafts and endovascular devices for dialysis access.
Market Dynamics
Industry Overview
The biotechnology industry, particularly the regenerative medicine sector, is experiencing significant growth. The demand for advanced therapies for vascular diseases, such as PAD and end-stage renal disease (ESRD), is increasing due to aging populations and the prevalence of risk factors like diabetes and obesity.
Positioning
Humacyte positions itself as a leader in bioengineered vascular tissue. Its HAV technology offers a potential competitive advantage by providing a readily available, off-the-shelf solution that avoids the need for autologous tissue harvesting or synthetic materials.
Total Addressable Market (TAM)
The TAM for vascular access and repair is estimated to be several billion dollars globally. Humacyte is targeting a significant portion of this market with HUMACYL. With a successful commercialization, the company can capture a substantial share, especially in the dialysis access market.
Upturn SWOT Analysis
Strengths
- Proprietary HAV technology
- Experienced leadership team
- Focus on unmet medical needs
- Potential for broad applications
Weaknesses
- Reliance on single product (HUMACYL)
- Regulatory approval risk
- Limited commercialization experience
- High cash burn rate
Opportunities
- Expansion into new therapeutic areas (e.g., PAD, vascular trauma)
- Partnerships with pharmaceutical companies
- Geographic expansion
- Positive clinical trial results
Threats
- Competition from established medical device companies
- Regulatory hurdles
- Reimbursement challenges
- Clinical trial failures
Competitors and Market Share
Key Competitors
- W. L. Gore & Associates (Gore)
- Getinge (GETI-B.ST)
- Medtronic (MDT)
Competitive Landscape
Humacyte's HAV technology offers a unique advantage compared to synthetic grafts from Gore and Getinge. However, its success depends on clinical trial results and regulatory approvals.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth has been centered on advancing its HAV technology through clinical trials and securing funding.
Future Projections: Future growth is contingent upon FDA approval of HUMACYL and successful commercialization. Analyst estimates vary widely depending on the perceived likelihood of regulatory success.
Recent Initiatives: Recent initiatives include completing Phase 3 clinical trials for HUMACYL in AV access and preparing for potential regulatory submissions.
Summary
Humacyte is a high-risk, high-reward biotechnology company poised on the cusp of potential commercialization. The success depends on the FDA approval of HUMACYL. The company needs to closely manage its cash runway and navigate the competitive landscape to realize its full potential, and needs to get to revenue generation soon.
Similar Companies
- Gore
- MDT
- GETI-B.ST
Sources and Disclaimers
Data Sources:
- Humacyte Inc. SEC Filings (10-K, 10-Q)
- Humacyte Inc. Investor Relations
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on publicly available information and analyst estimates and does not constitute financial advice. The data is subject to change, and investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Humacyte Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2021-08-26 | Founder, President, CEO & Director Dr. Laura E. Niklason M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 183 | Website https://www.humacyte.com |
Full time employees 183 | Website https://www.humacyte.com | ||
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.